Lung Cancer - Other

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors do not report synergic side...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

April 19, 2023 | Mark FergusonBronze Contributor

This study used lung cancer screening trial low dose CT scans to develop a model (Sybil) that predicts the likelihood of development of a lung cancer within the next year....

JANS Article

Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery Guidelines for the Prevention of Cancer-Associated Venous Thromboembolism in Thoracic Surgery

March 23, 2023 | Cameron LindSilver Contributor

Thoracic oncology patients are a high-risk group for venous thromboembolism (VTE). The ESTS and AATS panel reviewed the evidence using the GRADE approach and made twenty-four recommendations for VTE prophylaxis,...

JANS Article

FDA Approves Drug Which Makes Lung Cancer Glow

January 6, 2023 | Cameron LindSilver Contributor

The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light....

JANS Article

BMI, BMI Change, and Overall Survival in Patients With Lung Cancer

August 22, 2019 | Mark FergusonBronze Contributor

This study of over 25,000 pts from the International Lung Cancer Consortium identified underweight and severly obese patients as having poorer survival than others, whereas a survival advantage was evident...

JANS Article

Long-Term Follow-Up of Ground-Glass Nodules After 5 Years of Stability

August 20, 2019 | Aristotle ProtopapasGold Commentor

Interesting follow-up study of 208 pulmonary ground -glass opacities in 160 subjects, with a yield of three adenocardinomas.

...
JANS Article

In Global News: Expanded MitraClip Indications, Congenital Heart Surgery After Fukushima Accident, and Reducing Blood Utilization in Cardiac Surgery

March 15, 2019 | Claire Vernon

Drugs and Devices The US Food and Drug Administration (FDA) announced that the indications for the MitraClip™, made by Abbott, have been expanded to include secondary mitral regurgitation. Saranas, Inc,...

JANS Article

In Global News: Delirium After Cardiac Surgery, CALS in India, and Modeling Mitral Repair

February 22, 2019 | Claire Vernon

Patient Care and General Interest The Cardiac Surgery Advanced Life Support (CALS) protocol is expanding to India from the UK, as a cardiac surgical team at Sri Ramachandra Institute of...

JANS Article

Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer

November 14, 2018 | Claire Vernon

Thornblade and colleagues endeavored to develop and validate a model that would predict the 2-year risk of recurrence in patients with completely resected node-negative non-small cell lung cancer (NSCLC). Improved...

JANS Article

More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study

September 26, 2018 | Mark FergusonBronze Contributor

Using the National Cancer Database, the effect of the timing of computed tomography (CT) surveillance after resection of non-small cell lung cancer on survival was investigated. Survival was similar for...

JANS Article

The NELSON Trial Reports Large Survival Advantage for Lung Cancer Screening in Europe

September 25, 2018 | Joel DunningGold ContributorSilver Commentor

A seismic shift occurred today when the NELSON screening trial results were presented at the IASLC 19th World Conference on Lung Cancer (#WCLC2018). Hear from the CEO, Dr. Fred R....

JANS Article

Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC

September 25, 2018 | Mark FergusonBronze Contributor

This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III...

LOAD MORE
ADVERTISE ON CTSNET